Annexes Chiffres des publicationsde l’ICO 2014

AnnexesFigures of the publications of the ICO 2014

évoLution des pubLications depuis 2011

année nombre de publications

2011 169

2012 168

2013 180

2014 122

au sommaire

Les pubLications

Les 90 ans des centres rené gauducheau et pauL papin

Le docteur Stéphane Leduc et les premières guérisons de cancer par radiothérapie à Nantes et en France

La naissance des centres de lutte contre le cancer et de leur triple mission, soins/enseignement/recherche, dans les années “20”, à travers celle du CLCC d’Angers, le Centre Paul Papin

84

90

122 publications

et 1 263 POINTS SIGAPS

en 2014

ICO Rapport d’activité 2014 • 83

LIstE dEs puBLICAtIOns 2014

1 Yossi S, El Alouani C, Pointreau Y, Laccourreye L, Capitain O, Gustin P, et al. Sites de récidive après radiothérapie conformationnelle avec modulation d’intensité des carcinomes épidermoïdes des voies aérodi-gestives supérieures. Cancer Radiother 2014.

2 Bailly C, Eugène T, Couec ML, Strullu M, Frampas E, Campion L, et al. Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. Front Med (Lausanne) 2014;1:54.

3 Yossi S, Krhili S, Muratet JP, Septans AL, Campion L, Denis F. Early Assessment of Metabolic Response by 18F-FDG PET During Concomitant Radiochemotherapy of Non-Small Cell Lung Carcinoma Is Associated With Survival: A Retrospective Single-Center Study. Clin Nucl Med 2014.

4 Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, et al. Pathological Response and Circulating Tumor Cell Count Identifies Trea-ted HER2+ Inflammatory Breast Cancer Patients with Excellent Progno-sis: BEVERLY-2 Survival Data. Clin Cancer Res 2014.

5 Goineau A, Mahé MA, Paineau J, Campion L, Rio E. Fonctions sexuel-les après traitement du cancer rectal : impact des doses aux plexus pel-viens autonomes. Cancer Radiother 2014;18:757-62.

6 Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol 2014;41:613-22.

7 Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, et al. Identification by array comparative genomic hybridization of a new am-plicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Res 2014;16:466.

8 Carlier T, Ferrer L, Necib H, Bodet-Milin C, Rousseau C, Kraeber- Bodéré F. Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR. Phys Med Biol 2014;59:6417-30.

9 Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, et al. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer 2014;111:2058-66.

10 Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, et al. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol 2014;25:2351-6.

11 Goineau A, Campion L, Mahé MA. Prise en charge du sujet âgé en radiothérapie : mythes et perspectives. Geriatr Psychol Neuropsychiatr Vieil 2014;12:261-6.

12 Guérif S, Latorzeff I, Lagrange JL, Hennequin C, Supiot S, Garcia A, et al. Radiothérapie postopératoire des cancers de la prostate. Cancer Radiother 2014;18:517-23.

13 Créhange G, Roach M, Martin E, Cormier L, Peiffert D, Cochet A, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother 2014;18:524-34.

14 Khadige M, Peiffert D, Supiot S. Niveaux de preuve des nouvelles techniques de radiothérapie du cancer de la prostate. Cancer Radiother 2014;18:501-8.

15 Bibault JE, Denis F, Marchesi V, Lisbona A, Noël G, Mahé MA. Mise en œuvre de la radiothérapie stéréotaxique extracrânienne : enjeux de la formation initiale et continue. Cancer Radiother 2014;18:387-90.

16 Maingon P, Lisbona A. Radiothérapie en conditions stéréotaxiques : les prérequis. Cancer Radiother 2014;18:383-6.

17 Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, et al. Cost of adverse events during treatment with everolimus plus exe-mestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. J Med Econ 2014;17:837-45.

18 Salas S, Jiguet-Jiglaire C, Campion L, Bartoli C, Frassineti F, Deville JL, et al. Correlation between ERK1 and STAT3 expression and chemo-resistance in patients with conventional osteosarcoma. BMC Cancer 2014;14:606.

19 Cheray M, Nadaradjane A, Bonnet P, Routier S, Vallette FM, Cartron PF. Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness. Epigenomics 2014;6:267-75.

20 Pacaud R, Sery Q, Oliver L, Vallette FM, Tost J, Cartron PF. DNMT3L interacts with transcription factors to target DNMT3L/DNMT3B to speci-fic DNA sequences: role of the DNMT3L/DNMT3B/p65-NF?B complex in the (de-)methylation of TRAF1. Biochimie 2014;104:36-49.

21 Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, et al. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis 2014;5:e1291.

22 Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, et al. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood 2014;124:420-5.

23 Pichon B, Thillays F, Bourgier C, Mahé MA, Supiot S. Radiothérapie stéréotaxique hypofractionnée des métastases osseuses. Cancer Radio-ther 2014;18:342-9.

84 • ICO Rapport d’activité 2014

24 Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, et al. A phase II trial of high-dose chemotherapy (HDCT) supported by hemato-poietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) pa-tients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. Ann Oncol 2014;25:1775-82.

25 von Pawel J, Gorbounova V, Reck M, Kowalski DM, Allard A, Chadjaa M, et al. DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer 2014;85:224-9.

26 Tao Y, Vintonenko N, Garcia R, Marchesi V, Tomsej M, Bardet E, et al. Critères de qualité en radiothérapie des cancers de la tête et du cou sous l’égide de l’Intergroupe ORL. Bull Cancer 2014;101:481-5.

27 Baujat B, Périé S, Bardet E, Lacau St Guily J. Cancers de la cavité orale. Mise au point. Bull Cancer 2014;101:424-8.

28 Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in pa-tients with solid tumors. Cancer Chemother Pharmacol 2014;74:257-65.

29 Mignard V, Lalier L, Paris F, Vallette FM. Bioactive lipids and the control of Bax pro-apoptotic activity. Cell Death Dis 2014;5:e1266.

30 Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, et al. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multi-center cohort study. Breast 2014;23:561-6.

31 Ayyoub M, Memeo L, Alvarez-Fernández E, Colarossi C, Costanzo R, Aiello E, et al. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS. Cancer Immunol Res 2014;2:943-8.

32 Gorin JB, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al. Antitumor immunity induced after ? irradiation. Neoplasia 2014;16:319-28.

33 de Decker L, Campone M, Retornaz F, Berrut G, Kabeshova A, Molinié F, et al. Association between oestrogens receptor expressions in breast cancer and comorbidities: a cross-sectional, population-based study. PLoS One 2014;9:e98127.

34 Lefur E, Berton-Rigaud D, Boureau AS, Chapelet G, Berrut G, de Decker L. Early death in advanced ovarian cancer in older adults. J Am Geriatr Soc 2014;62:976-7.

35 Le Deroff C, Cherel M, Guertin A, Haddad F, Koumeir C, Métivier V, et al. EBT2 films response to alpha radiation at 48.3 MeV. Radiat Prot Dosimetry 2014;161:428-32.

36 Blanchard C, Mathonnet M, Sebag F, Caillard C, Kubis C, Drui D, et al. Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann Surg Oncol 2014;21:3534-40.

37 Linot B, Augereau P, Breheret R, Laccourreye L, Capitain O. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF pro-tocol): a retrospective study. Support Care Cancer 2014;22:2831-7.

38 Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, et al. Survival benefit of hyperthermic intraperitoneal chemo-therapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol 2014;21:3621-7.

39 Gratas C, Séry Q, Rabé M, Oliver L, Vallette FM. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. Onco-target 2014;5:2428-35.

40 Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, et al. ¹?F-FDG PET predicts survival after pretargeted radioimmunothe-rapy in patients with progressive metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2014;41:1501-10.

41 Cartron PF, Petit E, Bellot G, Oliver L, Vallette FM. Metaxins 1 and 2, two proteins of the mitochondrial protein sorting and assembly machi-nery, are essential for Bak activation during TNF alpha triggered apopto-sis. Cell Signal 2014;26:1928-34.

42 Bourgier C, Azria D, Fenoglietto P, Riou O, Almaghrabi MY, Supiot S, et al. Radiothérapie stéréotaxique extracrânienne et oligométastases. Cancer Radiother 2014;18:337-41.

43 Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014;111:17-24.

44 Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchertseifer F, Morgenstern A, et al. Comparative analysis of multiple myeloma treat-ment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. Nucl Med Biol 2014;41 Suppl:e30-5.

45 Rat C, Quereux G, Monegier du Sorbier M, Gaultier A, Bonnaud-Anti-gnac A, Khammari A, et al. Patients at elevated risk of melanoma: indivi-dual predictors of non-compliance to GP referral for a dermatologist consultation. Prev Med 2014;64:48-53.

ICO Rapport d’activité 2014 • 85

46 Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumu-mab with FOLFOX4 for first-line treatment of metastatic colorectal can-cer. Ann Oncol 2014;25:1346-55.

47 Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M, et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 2014;25:1152-8.

48 Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colom-bat P, et al. t(14;18) Translocation: A predictive blood biomarker for folli-cular lymphoma. J Clin Oncol 2014;32:1347-55.

49 Rousseau C, Rousseau T, Campion L, Lacoste J, Aillet G, Potiron E, et al. Laparoscopic sentinel lymph node versus hyperextensive pelvic dis-section for staging clinically localized prostate carcinoma: a prospective study of 200 patients. J Nucl Med 2014;55:753-8.

50 Galan-Moya EM, Treps L, Oliver L, Chneiweiss H, Vallette FM, Bidère N, et al. Endothelial secreted factors suppress mitogen deprivation-in-duced autophagy and apoptosis in glioblastoma stem-like cells. PLoS One 2014;9:e93505.

51 Douillard JY, Pirker R, O’Byrne KJ, Kerr KM, Störkel S, von Heyde-breck A, et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:717-24.

52 Rajerison H, Guérard F, Mougin-Degraef M, Bourgeois M, Da Silva I, Chérel M, et al. Radioiodinated and astatinated NHC rhodium complexes: synthesis. Nucl Med Biol 2014;41 Suppl:e23-9.

53 Servagi-Vernat S, Giraud P, Fenoglietto P, Azria D, Lisbona A, de La Rochefordière A, et al. Apport de la RCMI rotationnelle et de la tomothé-rapie hélicoïdale dans les cancers pelviens : étude dosimétrique pros-pective sur 51 patients. Cancer Radiother 2014;18:111-8.

54 Berrut G, Guérin O. La douleur du sujet âgé : une expression de la singularité qui interroge nos pratiques collectives. Geriatr Psychol Neuro-psychiatr Vieil 2014;12:4.

55 Pacaud R, Brocard E, Lalier L, Hervouet E, Vallette FM, Cartron PF. The DNMT1/PCNA/UHRF1 disruption induces tumorigenesis characterized by similar genetic and epigenetic signatures. Sci Rep 2014;4:4230.

56 Troussier I, Bensadoun RJ, Chamorey E, Lapeyre M, Baujat B, Ley-salle A, et al. Cervical node of unknown primary: patterns of care and factors influencing the choice of clinical target volumes. Oral Oncol 2014;50:e25-6.

57 Chan S, Campone M, Santoro A, Conte PF, Bostnavaron M, Nguyen L. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2014;73:903-10.

58 Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 2014;25:1128-36.

59 Bouvard B, Soulié P, Hoppé E, Georgin-Mege M, Royer M, Mesgouez-Nebout N, et al. Fracture incidence after 3 years of aromatase inhibitor therapy. Ann Oncol 2014;25:843-7.

60 Vernat SS, Ali D, Messina C, Pommier P, Dussart S, Puyraveau M, et al. Intensity modulated arc therapy in bilaterally irradiated head and neck cancer: a comparative and prospective multicenter planning study. Cancer Invest 2014;32:159-67.

61 Vo DD, Gautier F, Barillé-Nion S, Juin P, Levoin N, Grée R. Design, synthesis and biological evaluation of new inhibitors of Bax/Bcl-xL inte-raction in cancer cells. Bioorg Med Chem Lett 2014;24:1758-61.

62 Vera P, Dubray B, Palie O, Buvat I, Hapdey S, Modzelewski R, et al. Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. EJNMMI Res 2014;4:12.

63 Huynh TK, Meeus P, Cassier P, Bouché O, Lardière-Deguelte S, Adenis A, et al. Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer 2014;14:156.

64 Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol 2014;25:987-91.

65 Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorou-racil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014;32:1031-9.

66 Dantan E, Combescure C, Lorent M, Ashton-Chess J, Daguin P, Classe JM, et al. An original approach was used to better evaluate the capacity of a prognostic marker using published survival curves. J Clin Epidemiol 2014;67:441-8.

86 • ICO Rapport d’activité 2014

67 Toulmonde M, Bonvalot S, Méeus P, Stoeckle E, Riou O, Isambert N, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol 2014;25:735-42.

68 Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging 2014;41:1057-65.

69 Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and fol-low-up. Ann Oncol 2014;25:1462-74.

70 Jézéquel P, Juin PP, Campone M. “Bioinfomique” : un nouveau mot pour un nouveau champ de recherche. Bull Cancer 2014;101:118-9.

71 Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRO-DIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14.

72 Sorin T, Fyad JP, Pujo J, Colson T, Bordes V, Leroux A, et al. Incidence of occult contralateral carcinomas of the breast following mastoplasty aimed at symmetrization. Ann Chir Plast Esthet 2014;59:e21-8.

73 Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014;15:343-52.

74 Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Dic-cianni MB, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One 2014;9:e87210.

75 Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, et al. A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer. PLoS One 2014;9:e87761.

76 Dupoiron D, Richard H, Chabert-Desnot V, Devys C, Leynia P, Bois-dron-Celle M. In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps. Neuromodulation 2014;17:472-82; discussion 482.

77 Ayyoub M, Scarlata CM, Hamaï A, Pignon P, Valmori D. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone recep-tor negative status, high histologic grade, and poor survival. J Immuno-ther 2014;37:73-6.

78 André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014;15:267-74.

79 Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, et al. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol 2014;25:730-4.

80 Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, et al. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014;144:321-9.

81 Rauscher A, Frindel M, Maurel C, Maillasson M, Le Saëc P, Rajerison H, et al. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. Nucl Med Biol 2014;41 Suppl:e66-74.

82 Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, et al. Use of liposomal doxorubicin-cyclophospha-mide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 2014;117:253-9.

83 Clavreul A, Guette C, Faguer R, Tétaud C, Boissard A, Lemaire L, et al. Glioblastoma-associated stromal cells (GASCs) from histologically nor-mal surgical margins have a myofibroblast phenotype and angiogenic properties. J Pathol 2014;233:74-88.

84 Morfouace M, Lalier L, Oliver L, Cheray M, Pecqueur C, Cartron PF, et al. Control of glioma cell death and differentiation by PKM2-Oct4 interaction. Cell Death Dis 2014;5:e1036.

85 Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, et al. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer 2014;120:390-8.

86 Frindel M, Camus N, Rauscher A, Bourgeois M, Alliot C, Barré L, et al. Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice. Nucl Med Biol 2014;41 Suppl:e49-57.

ICO Rapport d’activité 2014 • 87

87 Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Ben-sadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preo-perative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15:184-90.

88 Bazin C, Vieillard V, Astier A, Paul M. Implementation of real-time identification analysis and quantification of chemotherapies preparations with a Multispec(®) analyser. Ann Pharm Fr 2014;72:33-40.

89 Patsouris A, Augereau P, Tanguy JY, Morel O, Menei P, Rousseau A, et al. Diagnostic différentiel entre récidive tumorale et radionécrose après radiothérapie stéréotaxique d’une métastase cérébrale. Cancer Radio-ther 2014;18:142-6.

90 Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, et al. Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014;50:953-62.

91 Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.

92 Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer 2014;110:1148-54.

93 Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Cha-rytensky H, et al. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol 2014;25:623-8.

94 Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, et al. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. Clin Colorectal Cancer 2014;13:14-26.e1.

95 Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 2014;25:409-15.

96 Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, et al. Everolimus plus exemestane as first-line therapy in HR?, HER2? advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2014;143:459-67.

97 Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, et al. The current and future role of the medical oncologist in the profes-sional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2014;25:9-15.

98 Lelorain S, Brédart A, Dolbeault S, Cano A, Bonnaud-Antignac A, Cousson-Gélie F, et al. How can we explain physician accuracy in asses-sing patient distress? A multilevel analysis in patients with advanced cancer. Patient Educ Couns 2014;94:322-7.

99 Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated ??Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol 2014;32:212-8.

100 Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 2014;12:50-4.

101 Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.

102 George A, Girault S, Testard A, Delva R, Soulié P, Couturier OF, et al. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma manage-ment: a retrospective study of 66 scans from a single institution. Nucl Med Commun 2014;35:282-90.

103 Krzakowski M, Bennouna J, Dansin E, Kowalski D, Hiret S, Penel N, et al. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol 2014;73:231-6.

104 Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonis-tic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 2014;164:258-65.

105 Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, et al. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol 2014;9:273-7.

106 Rautenberg T, Siebert U, Arnold D, Bennouna J, Kubicka S, Walzer S, et al. Economic outcomes of sequences which include monoclonal anti-bodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. J Med Econ 2014;17:99-110.

88 • ICO Rapport d’activité 2014

107 Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R? and NKG2D triggering. Cancer Res 2014;74:68-80.

108 Philippe Y, Espitalier F, Durand N, Ferron C, Bardet E, Malard O. Partial laryngectomy as salvage surgery after radiotherapy: oncological and functional outcomes and impact on quality of life. A retrospective study of 20 cases. Eur Ann Otorhinolaryngol Head Neck Dis 2014;131:15-9.

109 Isambert N, Ray-Coquard I, Italiano A, Rios M, Kerbrat P, Gauthier M, et al. Primary cardiac sarcomas: a retrospective study of the French Sar-coma Group. Eur J Cancer 2014;50:128-36.

110 Le Brun JF, Dravet F, Campion L, Classe JM. Coelioscopie diagnos-tique en cancérologie gynécologique, annexectomie bilatérale prophy-lactique : étude de faisabilité sur 22 cas. J Gynecol Obstet Biol Reprod (Paris) 2014;43:229-34.

111 Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multi-center prospective study. Eur Urol 2014;65:381-6.

112 Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, et al. 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplant 2014;49:131-7.

113 Servagi Vernat S, Ali D, Puyraveau M, Viard R, Lisbona A, Fenoglietto P, et al. Is IMAT the ultimate evolution of conformal radiotherapy? Dosi-metric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study. Phys Med 2014;30:280-5.

114 Brochard C, Hamy A, Michalak S, Aubé C, Picquet J, Nebout N, et al. Metastatic hepatocellular carcinoma: when surgery and successive palliative treatments lead to remission. Clin Res Hepatol Gastroenterol 2014;38:e19-22.

115 Noblet C, Chiavassa S, Paris F, Supiot S, Lisbona A, Delpon G. Unde-restimation of dose delivery in preclinical irradiation due to scattering conditions. Phys Med 2014;30:63-8.

116 Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 2014;25:424-7.

LIstE dEs puBLICAtIOns réALIséEs En tAnt qu’InvEstIGAtEur.

117 Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014;28:2367-75.

118 Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, et al. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas asso-ciated with different genomic alterations. Neuro Oncol 2014;16:1244-54.

119 Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681-90.

120 Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014;25:1475-84.

121 Reyes-Botero G, Dehais C, Idbaih A, Martin-Duverneuil N, Lahutte M, Carpentier C, et al. Contrast enhancement in 1p/19q-codeleted anaplas-tic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 2014;16:662-70.

122 Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269-77.

ICO Rapport d’activité 2014 • 89

55 Publications de l’ICO en 2014 à rajouter

aux 122 recensées en Mars 2015 = Total 177 publications recensées en Juin 2015

1. Werter IM, Schneiders FL, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Vγ9Vδ2 cells as antigen presenting cells for iNKT cell based cancer immunotherapy.

Oncoimmunology 2014;3:e955343.

2. Gorin JB, Guilloux Y, Morgenstern A, Chérel M, Davodeau F, Gaschet J. Using ?

radiation to boost cancer immunity? Oncoimmunology 2014;3:e954925.

3. Kraeber-Bodéré F, Barbet J. Challenges in nuclear medicine: innovative theranostic

tools for personalized medicine. Front Med (Lausanne) 2014;1:16.

4. Drouin E, Larra F, Bataille FR. La naissance des centres de lutte contre le cancer et de

leur triple mission, soins/enseignement/ recherche, dans les années < 20 >, à travers

celle du CLCC d'Angers, le Centre Paul Papin. Rev Soc Fr Hist Hop 2014:61-5.

5. Harly C, Peigné CM, Scotet E. Molecules and Mechanisms Implicated in the Peculiar

Antigenic Activation Process of Human V?9V?2 T Cells. Front Immunol 2014;5:657.

6. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et

al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472-

508.

7. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, et al.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-

cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol

2014;15:1442-50.

8. MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger

P, et al. Recommandations du GEFPICS concernant la phase pré-analytique pour

l'évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour

2014. Ann Pathol 2014;34:366-72.

9. Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A,

et al. Mise à jour 2014 des recommandations du GEFPICS pour l'évaluation du statut

HER2 dans les cancers du sein en France. Ann Pathol 2014;34:352-65.

10. Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, et al.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-

small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

Lancet Oncol 2014;15:1369-78.

11. Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, et al. The off-label use

of targeted therapies in sarcomas: the OUTC'S program. BMC Cancer 2014;14:870.

12. Smekens F, Létang JM, Noblet C, Chiavassa S, Delpon G, Freud N, et al. Split

exponential track length estimator for Monte-Carlo simulations of small-animal

radiation therapy. Phys Med Biol 2014;59:7703-15.

13. Ziouèche-Mottet A, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H,

et al. Eligibility criteria for intraoperative radiotherapy for breast cancer: study

employing 12,025 patients treated in two cohorts. BMC Cancer 2014;14:868.

14. Malgras B, Pasquier P, Savard DJ, Rouquie D, Baton O, Boulanger T, et al. Intake of

temporary abdominal closure with abdominal negative-pressure therapy in

management of nontraumatic abdominal surgical emergencies to avoid stoma. Am

Surg 2014;80:E314-6.

15. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell

MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for

uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 2014;24:S55-60.

16. Lacornerie T, Lisbona A, Mirabel X, Lartigau E, Reynaert N. GTV-based prescription

in SBRT for lung lesions using advanced dose calculation algorithms. Radiat Oncol

2014;9:223.

17. Denoyelle C, Lambert B, Meryet-Figuière M, Vigneron N, Brotin E, Lecerf C, et al.

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition

of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis 2014;5:e1445.

18. Pierga JY, Delva R, Pivot X, Espié M, Dalenc F, Serin D, et al. Bévacizumab et

taxanes dans le traitement de première ligne du cancer du sein métastatique : survie

globale et analyse de sous-groupes de l'étude ATHENA France. Bull Cancer

19. Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic Factors for

Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and

Development of a Novel Simplified Prognostic Model. Eur Urol 2014.

20. Drouin E, Bataille FR, Mahé MA. Le docteur Stéphane Leduc et les premières

guérisons de cancer par radiothérapie à Nantes et en France. Cancer Radiother

2014;18:709-12.

21. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, et al.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer.

Results of the DATECAN initiative (Definition for the Assessment of Time-to-event

End-points in CANcer trials). Eur J Cancer 2014;50:2983-93.

22. Tardif C, Nowak C, Sagan C, Frenel JS, Philippe HJ. Présentation anténatale atypique

d'un choriocarcinome gestationnel. Gynecol Obstet Fertil 2014;42:725-8.

23. Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, et al. Gemcitabine

plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer:

Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.

Eur J Cancer 2014;50:2975-82.

24. Ayyoub M, Valmori D. Comment on "differentiation of IL-17-producing effector and

regulatory human T cells from lineage-committed naive precursors". J Immunol

2014;193:3181.

25. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor

clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6:254ra125.

26. Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, et al. A phase II

study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. Ann Oncol

2014;25:2191-6.

27. Mahé MA, Barillot I, Chauvet B. Guide des procédures de radiothérapie externe et de

curiethérapie : présentation de la 2(e) édition. Cancer Radiother 2014;18:356-9.

28. Chauvet B, Mornex F, Mahé MA. Quelle technique pour quelle tumeur ? Enjeux

éthiques et méthodologiques, point de vue de la SFRO. Cancer Radiother

2014;18:379-82.

29. Lécuru F, Classe JM, Collinet P, Daraï E, Ferron G, Golfier F, et al. Vers quelle

chirurgie pour les cancers séreux avancés de l'ovaire ? J Gynecol Obstet Biol Reprod

(Paris) 2014;43:557-8.

30. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic

intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 2014;151:347-

53.

31. Mornex F, Mahé M, Mazeron JJ. Vers de nouveaux horizons. Cancer Radiother

2014;18:251-2.

32. Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, et al. Masitinib

in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a

randomized controlled open-label trial. Ann Oncol 2014;25:1762-9.

33. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib

treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a

surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.

34. Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A,

et al. A phase 1 dose escalation study of idarubicin combined with methotrexate,

vindesine, and prednisolone for untreated elderly patients with primary central nervous

system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol 2014;89:1024-9.

35. Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, et al. Radiation

plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-

comparative randomized phase II trial. Dig Liver Dis 2014;46:950-5.

36. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, et al. Validation of

dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic

therapy for solid tumors: the French multicenter support for innovative and expensive

techniques study. Invest Radiol 2014;49:794-800.

37. Gueugnon F, Cartron PF, Charrier C, Bertrand P, Fonteneau JF, Gregoire M, et al.

New histone deacetylase inhibitors improve cisplatin antitumor properties against

thoracic cancer cells. Oncotarget 2014;5:4504-15.

38. Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, et al. Nouvelle

perspective de traitement dans le cancer bronchique non à petites cellules (CBNPC).

Place de l'afatinib : un inhibiteur oral et irréversible de la famille ErbB. Bull Cancer

2014;101:647-52.

39. Senellart H, Hiret S, Guerin-Meyer V, Bennouna J. Place des traitements d'entretien et

de la pause thérapeutique complète dans la prise en charge des cancers colorectaux

métastatiques non résécables. Bull Cancer 2014;101:619-25.

40. Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, et al.

Catumaxomab with and without prednisolone premedication for the treatment of

malignant ascites due to epithelial cancer: results of the randomised phase IIIb

CASIMAS study. Med Oncol 2014;31:76.

41. Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, et al. Oral

vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell

lung cancer: final results of an International randomized phase II study (NAVotrial

01). Clin Lung Cancer 2014;15:258-65.

42. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, et al.

Delivering precision medicine in oncology today and in future-the promise and

challenges of personalised cancer medicine: a position paper by the European Society

for Medical Oncology (ESMO). Ann Oncol 2014;25:1673-8.

43. Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, et al.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655

(CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Clin Cancer Res 2014;20:4251-61.

44. Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, et al.

CD1d-restricted antigen presentation by V?9V?2-T cells requires trogocytosis. Cancer

Immunol Res 2014;2:732-40.

45. Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, et al. Actinomycin D,

cisplatin, and etoposide regimen is associated with almost universal cure in patients

with high-risk gestational trophoblastic neoplasia. Eur J Cancer 2014;50:2082-9.

46. Mery É, Hommell-Fontaine J, Capovilla M, Chevallier A, Bibeau F, Croce S, et al.

Mésothéliome malin péritonéal : mise au point et données actuelles. Ann Pathol

2014;34:26-33.

47. Dartigues P, Isaac S, Villeneuve L, Glehen O, Capovilla M, Chevallier A, et al. Mise

au point sur le pseudomyxome péritonéal. Aspects anatomo-pathologiques, et

implications thérapeutiques. Ann Pathol 2014;34:14-25.

48. Villeneuve L, Isaac S, Glehen O, Capovilla M, Chevallier A, Croce S, et al. Réseau

RENAPE : vers une nouvelle organisation des soins pour le traitement des tumeurs

rares du péritoine. Description du réseau et rôle des pathologistes. Ann Pathol

2014;34:4-8.

49. Ardillon L, Lefrançois A, Graveleau J, Fouassier M, Ternisien C, Sigaud M, et al.

Management of bleeding in severe factor V deficiency with a factor V inhibitor. Vox

Sang 2014;107:97-9.

50. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, et al. High

hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J

Cancer 2014;135:1165-77.

51. Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, et al. Second-line

therapy in elderly patients with advanced nonsmall cell lung cancer. Eur Respir J

2014;43:240-9.

52. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan

AM, et al. Associations of common breast cancer susceptibility alleles with risk of

breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res

2014;16:3416.

53. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, et al.

Association of age with survival in patients with metastatic colorectal cancer: analysis

from the ARCAD Clinical Trials Program. J Clin Oncol 2014;32:2975-84.

54. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with

resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Lancet Oncol 2014;15:862-73.

55. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al.

Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med

2014;371:424-33.